Study Aims to Support Patients, Improve Care, and Accelerate Research for Rare Disorder by Putting Power in Patients’ Hands
San Francisco – February 28, 2018 – Spruce Biosciences, a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders, today announced the launch of its CAH Natural History Study. The study will enable patients with congenital adrenal hyperplasia (CAH), a rare disease, to contribute their experiences to advance knowledge of the disease, including its management and treatment. Spruce is launching the study in conjunction with World Rare Disease Day, an annual observance to raise awareness about rare diseases and the impact of living with them on patients, families and caregivers.
Although CAH is part of the newborn screening program and highly identifiable – unlike many other rare diseases – there are currently no FDA-approved therapies for CAH. The CAH Natural History Study is designed to collect health-related patient information and serve as a resource to advance education, advocacy, and research initiatives, as well as serve as a recruitment database that can be used to address the difficulties associated with enrolling patients into clinical trials necessary to advance the development of new therapeutics.
“World Rare Disease Day promotes awareness and support for people impacted by rare diseases. Our decision to launch the CAH Natural History Study in conjunction with this annual observance underscores our pledge to conduct research that generates real-world patient outcomes in CAH,” said Dr. Alexis Howerton, CEO, Spruce Biosciences. “We believe this research will help transform the collective understanding and approach to treating CAH, helping patients and families get optimal care for generations to come.”
CAH is a rare endocrine disorder caused by genetic mutations resulting in the inability to produce the critical ‘stress’ hormone, cortisol. The most common form of CAH, 21 hydroxylase deficiency, affects approximately 1 in 10,000 to 15,000 people in the United States.
Patients interested in participating in the CAH Natural History Study can visit the site here.
Spruce is currently conducting a Phase 2 clinical trial to assess the safety and efficacy of SPR001in adults with classic CAH. For more information on Spruce Biosciences and its lead clinical program for CAH, please visit sprucebiosciences.com.
About Spruce Biosciences
Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders. The Spruce team is leveraging their extensive expertise in endocrinology and orphan drug development to meet the significant unmet need of patients suffering from rare endocrine diseases. Spruce’s lead product candidate, SPR001, has a novel and clinically verified mechanism of action (MOA) and is currently in Phase 2 clinical trials for congenital adrenal hyperplasia, a rare disease that is screened in newborns and for which there is not yet an FDA-approved therapy. The Company is headquartered in San Francisco and closed a Series A Financing of $20 million in 2016. For more information on Spruce, please visit sprucebiosciences.com.